Clinical Trial Update: Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the immunogenicity and safety of Imovax Polio in Chinese infants compared with local oral poliovirus vaccine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• IMOVAX Polio (inactivated poliovirus vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Poliomyelitis, Polio | Phase 3 | Status: COMPLETED